First dose-ranging study of remimazolam in Japanese patients undergoing gastrointestinal endoscopy: Phase II investigator-initiated clinical trial.

Ryoji IchijimaHisatomo IkeharaTakeshi MaedaTomomi SugitaToshiki HoriiAya IwaoKanako OguraChika KusanoYuko KondoTakahiro SuzukiTakuji Gotoda

Published in: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2022)

Initial and additional doses of 3 mg and 1 mg/dose of remimazolam, respectively, were shown to be effective and safe for sedation during gastrointestinal endoscopy in Japanese patients.

Keyphrases

phase ii
clinical trial
open label
patients undergoing
double blind
small bowel
phase iii
placebo controlled
study protocol
randomized controlled trial
mechanical ventilation
intensive care unit